Post Profile

Popular immunotherapy target turns out to have a surprising buddy

(Netherlands Cancer Institute) The majority of current cancer immunotherapies focus on PD-L1. This well-studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. Researchers from the Netherlands Cancer Institute publish these findings in the leading journal Nature on Aug. 16.
read more


Related Posts

Researchers evaluating immunotherapy approaches for treating metastatic kidney, prostate, bladder cancers

Health : Medical News Today

Researchers at the Roswell Park Cancer Institute (RPCI) Center for Immunotherapy are enrolling patients in three different clinical trials of novel immunotherapy approaches for treating genitourinary cancers. One of the studies will...

NIH Awards Karmanos Cancer Institute Breast Cancer Researchers Nearly $3 Million For Ground-Breaking Immunotherapy Clinical Study

Health : Medical News Today

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit have received a nearly $3 million, five-year research project (RO1) grant from the National Institutes of Health to study a potentially ground-breaking immunotherapy...

Researchers discover new immunotherapy combination effective at killing cancer cells

Health : EurekAlert: Health

(University of Calgary) Researchers at the University of Calgary recently discovered an immunotherapy that uses existing cancer drugs in a whole new way. 'What we found is a combination of cancer therapies that complement each other...

Cellular immunotherapy targets a common human cancer mutation

Diseases & Conditions / Cancer : EurekAlert: Cancer

(NIH/National Cancer Institute) n a study of an immune therapy for colorectal cancer that involved a single patient, a team of researchers at the National Cancer Institute identified a method for targeting the cancer-causing protein...

Boosting immune cell memory to improve vaccines and cancer immunotherapy

Diseases & Conditions / Cancer : ScienceDaily: Cancer

Drugs that activate the cells' proteasome, or recycling center, tip the balance in favor of memory CD8+ T cells, studies on mice show. This approach could be used to improve how well vaccines and immunotherapies work and how long th...


Copyright © 2016 Regator, LLC